




# PALLADIUM-CATALYSED COUPLING OF OXANORBORNENES AND TERTIARY PROPARGYLIC CARBOXYLATES: A SIMPLE ACCESS TO ALLENYLIDENECYCLOPROPANES

**Aymeric LEPRONIER, Hervé CLAVIER, Laurent GIORDANO, Gérard BUONO**

Chirosciences Team - Institut des Sciences Moléculaires de Marseille –  
UMR CNRS 7313 - Université Aix-Marseille  
Campus Scientifique de Saint Jérôme, 13397 Marseille Cedex 20

Secondary phosphine oxides (SPOs) and more particularly their P(III) form, phosphinous acids, have recently attracted much attention due to their ability to coordinate various transition metals giving them interesting catalytic properties.<sup>[1]</sup> Over the last decade, our group has been involved in the synthesis of SPOs as well as their application in coordination chemistry and in homogeneous catalysis.<sup>[2]</sup> For example, we have developed palladium-mediated tandem [2+1] cycloaddition/ring expansion sequence of norbornene derivatives with tertiary propargylic acetates giving rise to bicyclo[3.2.1]octadiene compounds.<sup>[3]</sup> In order to develop a methodology giving a straightforward access to functionalized seven-membered carbocycles, we intended to extend this catalytic transformation to oxanorbornene derivatives. Surprisingly, whereas the expected product was isolated in low yields for optimized reaction conditions, allenylidenecyclopropane cycloadducts were found to be the major or unique product. Herein, we will describe this new palladium-catalysed [2+1] cycloaddition that was investigated for various oxanorbornenes and tertiary propargylic carboxylates. A series of allenylidenecyclopropanes was obtained in good yields.



## References

- [1] (a) L. Ackermann, *Synlett* **2006**, 1557 (b) T.M. Shaikh, C.-M. Weng, F.-E. Hong, *Coord. Chem. Rev.* **2011**, doi:10.1016/j.ccr.2011.11.007.
- [2] (a) T. Achard, L. Giordano, A. Tenaglia, Y. Gimbert, G. Buono, *Organometallics* **2010**, 29, 3936. (b) J. Bigeault, L. Giordano, G. Buono, *Angew. Chem. Int. Ed.* **2005**, 44, 4753. (c) T. Achard, A. Lepronier, Y. Gimbert, H. Clavier, L. Giordano, A. Tenaglia, G. Buono, *Angew. Chem. Int. Ed.* **2011**, 50, 3552.
- [3] J. Bigeault, I. de Riggi, Y. Gimbert, I. Giordano, G. Buono, *Synlett* **2008**, 1071.





# PHOSPHORUS REAGENTS, A COLORFUL PALETTE FOR ORGANIC SYNTHESIS AND NEW BIOMOLECULES



David VIRIEUX


*Institut Charles Gerhardt – UMR 5253 – AM2N - Ecole Nationale Supérieure de Chimie de Montpellier  
8, Rue de l'École Normale – 34296 Montpellier Cedex 5 – France  
David.virieux@enscm.fr*

Modern organic synthesis requires the development of highly chemo- and stereoselective methods. Often mild and environmentally friendly, domino reactions are constituting a powerful tool shortening synthesis and substantially decreasing the wastes. In this context, starting from underused phosphinyl allenes, we have developed an effective synthesis of phosphorus heterocycles **1** through a hydrophosphination / isomerisation / Michael / Michael sequence. In another way, understanding the role played by trivalent nucleophilic phosphorus reagents allowed the formation of highly functionalized phosphine oxides through a four-component reaction or heterocycles by an organocatalyzed domino process.



Besides the interest they may show in organic synthesis, organophosphorus compounds also exhibit special characteristics that make them unique in the field of biomolecules. Then, the phosphinolactone group can be regarded as a surrogate of lactol and could present an opportunity for the medicinal chemists to explore uncovered regions of chemical space. In addition to its isosteric relationship with the lactol group, phosphinolactone is an outstanding hydrogen bond acceptor and metal complexing agent which makes it an attractive structural motif for drug discovery.

Recently, we developed two different families of heterocycles which present the 1,2-oxaphosphinane **2** or the 1,4,2-oxazaphosphinane heterocyclic cores. The antiproliferative properties of oxaphosphinanes **2** were determined on C6 glial cells confirming their glycoside-like analogy.



The chemistry of the organophosphorus compounds may bring new developments either in organic synthesis or for dedicated applications.



## **Friday Afternoon**

---

### **BOLTE Benoît**

Gold(I) and Brønsted acid-catalyzed diastereocontrolled construction of variously substituted tetrahydropyrans

### **CHAMAS Zein el abidine**

Synthesis of pentacyclic heterocycles through a regio- and diastereoselective cascade process

### **MAOUGAL Esma**

Synthesis of analogue of AZT with triazole moiety

### **PESSET Bénédicte**

TonB machinery: a new bacterial target for peptidic antibiotics

### **MONTEL Sonia**

Synthesis of new fosmidomycin analogues as potential inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

### **PAGOAGA Bernard**

Synthesis of new perylene derivatives and applications in organic

### **AOUN Sameh**

Synthesis of new therapeutic agents targeting the bone system

---

### **Dr. COUDRET Christophe**

Chemical dynamics, photochromism, nanosciences




## GOLD(I) AND BRØNSTED ACID-CATALYZED DIASTEREOCONTROLLED CONSTRUCTION OF VARIOUSLY SUBSTITUTED TETRAHYDROPYRANS


**Bolte B., Gagosz, F.**

*DCSO, UMR 7652, CNRS/Ecole Polytechnique, 91128 Palaiseau, France.*

Allenes are valuable substrates or intermediates for the preparation of numerous motifs in organic synthesis. Gold (I) complexes have proved their ability to promote hydride shifts onto  $\pi$ -systems, and their efficiency to perform a reverse polarisation hydrofunctionalizations of allenes. Benzyl ethers can be used as hydride donors to induce 1,5-hydride shifts. The resulting oxonium species can be trapped to furnish various cyclized products.




Depending on the degree of substitution of the allene, the nature of the catalyst and the reaction time, an hydride transfer/cyclization sequence was observed, leading to variously substituted tetrahydropyrans. Several conditions have been developed in order to obtain the desired scaffold in excellent selectivities. The 6-membered ring transition state enables an excellent control of the newly-formed asymmetric centers, which makes this transformation highly diastereoselective.



### References:

- Bolte, B.; Gagosz, F. *J. Am. Chem. Soc.*, 2010, 132 (21), pp 7294–7296  
Bolte, B.; Gagosz, F. *J. Am. Chem. Soc.*, 2011, 133 (20), pp 7696–7699




## SYNTHESIS OF PENTACYCLIC HETEROCYCLES THROUGH A REGIO-AND DIASTEREOSELECTIVE CASCADE PROCESS

**Zein el abidine CHAMAS, Victor MAMANE, Yves FORT**

Laboratoire SRSMC, UMR 7565, BP 70239,  
Bd des Aiguillettes, 54506 Vandoeuvre-Lès-Nancy-France  
Faculté des Sciences et Technologies, Université de Lorraine  
Zein.El-Abidine-Chamas@srsmc.uhp-nancy.fr

A new family of pentacyclic compounds incorporating a central 1,2-dihydropyridine core was obtained through a cascade reaction between 2-formylbenzene boronic acid and 2-halopyridines bearing additional reactive functions in 5-position. The cascade process was initiated by a palladium-catalyzed cross-coupling reaction and was followed by two successive nucleophilic cyclizations; the first cyclization performed on the pyridine nitrogen and the second occurred regioselectively on the adjacent carbon atom. Alternatively, when the reactive function in 5-position was an aldehyde, a cascade reaction starting from 2-chloro-5-bromopyridines and two equivalents of boronic acid was operating.



The crystal structures of two pentacyclic compounds were obtained and showed unambiguously the *trans* relationship between R and H. Overall, four new bonds and two stereocenters were produced during the cascade process and the observed regio- and diastereoselectivity were interpreted by Density Functional Theory calculations which evidenced the occurrence of an internal chelation in the transition state.

These new pentacyclic compounds show strong fluorescence emission which were quantitatively measured.

Z. Chamas, O. Dietz, E. Aubert, Y. Fort and V. Mamane *Org Biomol Chem* **8**(21):4815-8 (2010)



## SYNTHESIS OF ANALOGUES OF AZT WITH TRIAZOLE MOIETY


**Esma Maougal, Monique Mathé-Allainmat, Didier Dubreuil and Jacques Lebreton.**

Laboratoire **CEISAM** (Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation),  
Groupe **SYMBIOSE** (Synthèse Multiétape et BIOScienceE),  
UMR CNRS 6230, 2 rue de la Houssinière-BP 92208-44322 Nantes Cedex 3

Currently, **AIDS** (Acquired Immune Deficiency Syndrome) is considered a pandemic, causing about 1.8 million deaths between 1981 (date on which the first case of AIDS was identified) and 2009.<sup>1</sup> AZT or 3'-azido-3'-deoxythymidine was the first antiretroviral approved for the treatment of AIDS<sup>2</sup>. This compound, due to the absence of the hydroxyl group in position 3', inhibits reverse transcriptase, and prevents the extension of the viral DNA chain and finally viral replication of the RNA.<sup>3</sup>

Herpes is a viral disease caused by both Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2). This pathogen, in its various forms, affects more than 90% of the population worldwide. Acyclovir or 9-[[2-hydroxyethoxy]-methyl]-guanosine (ACV) is an acyclic analogue of the natural nucleoside 2'-deoxyguanosine, considered as the first choice of treatment for herpes simplex virus types 1 and 2. ACV is also deprived of this 3'-OH function presents in the natural nucleosides, inhibits herpes DNA polymerase<sup>4</sup>, and behaving as a "suicide inhibitor"

As part of the discovery of new molecules to complete the therapeutic arsenal directed to these two viral diseases, we are interested in the synthesis of a new family of antiretroviral of the AZT type with a 1,2,3-triazole-1,4-disubstituted moiety<sup>5</sup> (see Scheme below). These compounds were tested against HIV in collaboration with the group of Professor Raymond F. Schinazi (Emory University School of Medicine/Veterans Affairs Medical Center, Atlanta, Georgia 30033, USA) and against herpes in collaboration with Professor Nathalie Bourgougnon (Université de Bretagne Sud, Laboratoire de Biotechnologie et Chimie Marines, Vannes).



### References

1. <http://www.unaids.org>
2. E. De Clerk, *Int. J. Antimicrob. Ag*, **2009**, 33, 307.
3. Y. Pommier, A. A. Johnson, C. Marchand, *Nat. Rev. Drug Discov.*, **2005**, 4, 236.
4. G. B. Elion, P. A. Furman, J. A. Fyfe, P. de Miranda, L. Beauchamp, H. J. Schaeffer. *Proc. Natl. Acad. Sci.*, **1977**, 74, 5716.
5. M. V. Gil, M. J. Arévalo, O. Lopez, *Synthesis*, **2007**, 11, 1589.



## TonB MACHINERY: A NEW BACTERIAL TARGET FOR PEPTIDIC ANTIBIOTICS

**Bénédicte Pesset, Isabelle Schalk, Gaëtan Mislin**

***"Transports Membranaires Bactériens", IREBS UMR 7242***

*ESBS, Bvd Sébastien Brant, 67400 Illkirch-Graffenstaden*

Highly pathogenic Gram-negative bacteria such as *Yersinia pestis*, *Burkholderia mallei* and *Burkholderia pseudomallei* are listed as potential biological weapons on the battlefields or in the frame of bioterrorist attacks. Furthermore, antibiotic resistance is increasing dramatically: cases of resistance have now been reported for all antibacterial drugs, even those recently approved. Therefore, it is absolutely crucial to identify new biological targets and to develop new antimicrobial agents less prone to resistance. For this purpose, we focus our project on iron acquisition mechanisms in *Pseudomonas aeruginosa*, an opportunistic pathogen particularly resistant to most all the available antibiotics, and genetically close to the bacteria cited above.

In iron depleted medium, bacteria produce low molecular weight compounds able to chelate Fe(III), called siderophores.<sup>1</sup> Iron(III)-siderophore complexes are recognized by a specific outer membrane receptor before being actively transported into the periplasm. This translocation required the energy provided by a TonB-ExbB-ExbD protein complex embedded in the inner membrane, the TonB machinery. This energy transducer is involved as well in the uptake of others essential nutrients.<sup>2</sup> Moreover, sequence alignments of the periplasmic domain of TonB and various TonB-dependent transporters showed that the interaction domain is highly conserved. Last but not least, the bacterial proliferation is seriously affected when the TonB energy transducer is mutated.<sup>3</sup> Therefore inhibitors of this complex molecular machinery are potential antibacterial agents, without effects on the host since human beings do not express neither the target protein nor an homologous protein.

Our inhibition strategy consists in a direct disruption of the TonB protein / transporter interaction using molecules containing a peptidic moiety linked to a heterocyclic anchor, able to sequester TonB in the periplasm. The synthesis of our potential antibiotics will be presented, and their efficiency will be evaluated using various biological tests (MIC, iron uptake pathway inhibition, surface plasmon resonance, etc). In parallel we developed a siderophore-based vector able to address TonB inhibitors to a specific bacteria specie using the Trojan Horse produg strategy.<sup>4</sup>

***"It is absolutely crucial to identify new biological targets and develop new antimicrobial agents less prone to resistance. In this context, inhibitors of the TonB machinery are potential new antibacterial agents, without effects on the host."***

### References

1. Hider, R. C.; Kong, X. *Nat. Prod. Rep.* **2010**, *27*, 637-657.
2. Schauer K.; Rodionov D. A.; De Reuse H. *Trends Biochem. Sc.* **2008**, *33*, 330-338.
3. Zhao Q.; Poole K. *J. Bacteriol.* **2002**, *184*, 1503-1513.
4. Noël, S.; Gasser, V.; Pesset, B.; Hoegy, F.; Rognan, D.; Schalk, I. J.; Mislin, G. L. A. *Org. Biomol. Chem.* **2011**, *9* (24), 8288-8300.





## SYNTHESIS OF NEW FOSMIDOMYCIN ANALOGUES AS POTENTIAL INHIBITORS OF 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE


Sonia Montel<sup>a</sup>, Camille Midrier<sup>a</sup>, Lothar Willms<sup>b</sup>, Ralf Braun<sup>b</sup>, Klaus Haaf<sup>b</sup>, Jean-Luc Pirat<sup>a\*</sup> and David Virieux<sup>a\*</sup>

<sup>a</sup>Institut Charles Gerhardt - AM2N – ENSCM - 8, Rue de l'Ecole Normale-F-34296 Montpellier Cedex 5 – France

<sup>b</sup>Bayer Cropscience AG – Chemistry Frankfurt, G836 - Industriepark Hoechst  
D- 65926 Frankfurt am Main - Germany

The non-mevalonate pathway is an alternative metabolic pathway leading to the formation of isopentenyl pyrophosphate. It is widely found in higher plants, protozoa or bacteria but interestingly has no equivalent in mammals.<sup>1</sup> Identifying a non-mevalonate pathway inhibitor would greatly contribute to the search for safer herbicides. The unique properties of 1-deoxy-*D*-xylulose 5-phosphate reductoisomerase (DXR) make it remarkable and a central target for drug design. The Fosmidomycin, a phosphonohydroxamic acid isolated from *Streptomyces lavendulae*, acts through the inhibition of DXR.<sup>2</sup>

Synthesis of Fosmidomycin analogues appears to be interesting in order to obtain new potential herbicides. We focused on the modifications of the complexing subunit which was sparsely studied to date. The X-Ray diffraction experiment of DXR co-cristallized with Fosmidomycin shows that in the enzyme site, the phosphonic group interacts with a highly specific and polar pocket. By contrast, the cation complexing unit involving the hydroxamic acid offers the possibilities of structural modifications or variations. Dedicated syntheses on this topic will be presented.



<sup>1</sup> P. J. Proteau, *Bioorg. Chem.* **2004**, 32, 483-493.

<sup>2</sup> S. Steinbacher, J. Kaiser, W. Eisenreich, R. Huber, A. Bacher, F. Rohdich, *J. Biomol. Chem.* **2003**, 20, 18401-18407.



# SYNTHESIS OF NEW PERYLENE DERIVATIVES AND APPLICATIONS IN ORGANIC

**Bernard Pagoaga, Louis Giraudet, Norbert Hoffmann**

Université de Reims Champagne-Ardenne, UFR Sciences, B.P 1039, F-51687 Reims Cedex 2

Perylene bisimides are dyes studied for their spectroscopic properties and their ability to self-assemble. They can be used in protein labelling, single molecule spectroscopy, crystalline liquids, etc. They are also n-type semi-conductors and are focused in the field of organic electronics for one decade. Their air-stability, customization ability in several positions (bay, ortho, peri) and solubility in most organic solvents make them great candidates for integration in Organic-Field Effect Transistor<sup>1</sup>.

In this goal we synthesized a large variety of perylene derivatives using the Suzuki-Miyaura coupling reaction on 1,6,7,12-tetrachloroperylene bisimides, 1,7-dibromoperylene bisimides and more uncommon 1,12-dichloroperylene bisimides (Fig. 1)<sup>2</sup>. These products have then been placed in devices (OFETs) so their mobility could have been determined.




Fig. 1 : a) Suzuki-Miyaura coupling to obtain new perylene derivatives, b) Example of an electrical characterization measured on a commercial derivative and microscopic image of the crystals.

“Rylene diimides are a robust, versatile class of polycyclic aromatic electron-transport materials with excellent thermal and oxidative stability and high electron mobilities; they are, therefore, promising candidates for a variety of organic electronics applications”

## References

[1] Li, C.; Wonneberger, H. *Advanced Materials* **2012**, 24, 613-636.

[2] Zhen, Y.; Qian, H.; Xiang, J.; Qu, J.; Wang, Z. *Organic Letters* **2009**, 11, 3084-3087.



# SYNTHESIS OF NEW THERAPEUTIC AGENTS TARGETING THE BONE SYSTEM

**Sameh Aoun, Jacques Lebreton, Monique Mathé-Allainmat**

Laboratoire CEISAM, UMR CNRS 6230, Université de Nantes,  
Faculté des Sciences et des Techniques,  
02 rue de la Houssinière – BP 92208 – 44322 NANTES Cedex 3

The bone tissue is a connective tissue composed of a mineral part, made of calcium phosphate in the form of hydroxyapatite crystals (HA :  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ), and of an organic part containing an extracellular matrix and numerous specialized cells (osteoclasts, osteoblasts...) <sup>1</sup>. These different components are balanced and every malfunction leads to the appearance of specific pathologies such as osteoporosis which is a disease characterized by an important bone resorption.

Nowadays, different drugs are proposed to treat bone diseases such as zoledronic acid (or zoledronate, figure 1) which is the most efficient anti-resorptive commercialized agent. Its high activity on bone is particularly due to the presence of a Hydroxy-BisPhosphonic acid (HBP) function which strongly chelate hydroxyapatite crystals.

This efficient binding property of HBPs to the surface of bone makes them potential tools to target bone and deliver various drugs to it <sup>2,3</sup>. Such a concept could be expressed by the design of "bifunctional molecules" where a HBP function is attached to a linker bearing a drug on the other end (figure 2). In the laboratory, we have recently developed this concept to potentially treat rheumatoid arthritis with attachment of NSAID (Non-Steroidal Anti-Inflammatory Drug) to the vector <sup>4</sup>.

This communication will outline different synthetic routes to a family of "bifunctional molecules" with the application of a novel procedure to access to complex HBPs starting from carboxylic acid precursors <sup>5,6</sup>.




Figure 1




Figure 2

## References:

<sup>1</sup> Green, J. *The physicochemical structure of bone: cellular and noncellular elements. Miner Electrolyte Metab.* **1994**, *20*, 7-15.

<sup>2</sup> Uludag, H. *Current Pharmaceutical Design*, **2002**, *8*, 99-110.

<sup>3</sup> Zhang, S.; Gangal, G.; Uludag, H. *Chem. Soc. Rev.*, **2007**, *36*, 507-531.

<sup>4</sup> Egorov, M.; Fortun, Y.; Heymann, D.; Lebreton, J.; Mathe, M.; Padrines, M.; Redini, F. *PCT Int. Appl.* **2009**, WO 2009083614.

<sup>5</sup> Egorov, M.; Fortun, Y.; Heymann, D.; Lebreton, J.; Mathe, M.; Padrines, M.; Redini, F. *PCT Int. Appl.* **2009**, WO 2009083613.

<sup>6</sup> Egorov, M.; Aoun, S.; Padrines, M.; Redini, F.; Heymann, D.; Lebreton, J.; Mathe-Allainmat, M. *Eur. J. Org. Chem.*, **2011**, *35*, 7148-7154.

« La vérité est parfaite pour les mathématiques, la chimie,  
la philosophie, mais pas pour la vie. »

Ernesto Sabato



## CHEMICAL DYNAMICS, PHOTOCROMISM, NANOSCIENCES

**Christophe Coudret**

*Laboratoire des IMRCP, 118 route de Narbonne, Bâtiment 2R1, 31062 Toulouse Cedex 09*

Chemical Dynamics: triviality or the next frontier of chemistry?

Although obviously part of any chemical transformation, the time evolution of a chemical system is poorly considered especially in academic organic synthetic chemistry. Most of the text book studies rely on standard techniques such as quasi-stationary states or pseudo-first order conditions in order to smooth any weird behavior. However thanks to the progress of numerical treatments it is now possible to treat raw data without any approximation according to a hypothetical kinetic scheme ("hard-modeling"). This approach is also used in Chemometry: i.e. how to process complex spectroscopic data (typically a fluorescence decay).

The Chemical Dynamics will be exemplified in the lecture following two directions: the deliberate creation of chemical complexity using photochromic reactive dyes, and the spontaneous absolute asymmetric synthesis (Soai reaction) in which a product catalyses its own creation.

# Authors Index

## PLENARY LECTURES

### **PR JEROME LACOUR**

---

Département de Chimie Organique  
Université de Genève  
30 quai Ernest Ansermet  
1211 Genève 4 / Suisse  
[Jerome.Lacour@unige.ch](mailto:Jerome.Lacour@unige.ch)

### **PR DAVID VIRIEUX**

---

Institut Charles Gerhardt Montpellier  
Ecole Nationale Supérieure de Chimie  
8 rue de l'Ecole Normale  
34296 Montpellier Cedex 5  
[david.virieux@enscm.fr](mailto:david.virieux@enscm.fr)

### **DR STELLIOS ARSENIYADIS**

---

Laboratoire de Chimie Organique, ESPCI  
10 rue Vauquelin  
75231 Paris Cedex 05  
[stellios.arseniyadis@espci.fr](mailto:stellios.arseniyadis@espci.fr)

### **DR DAVID BERNIER**

---

Disease Control Chemistry, Bayer S.A.S. / Bayer CropScience  
CS 99163 - 14 impasse Pierre Baizet  
F-69263 LYON Cedex 09  
[David.bernier@bayer.com](mailto:David.bernier@bayer.com)

### **DR FREDERICK CALO**

---

BASF SE, GVA/HC  
B009 - 224  
67056 Ludwigshafen, Germany  
[frederick.calo@basf.com](mailto:frederick.calo@basf.com)

### **DR SANDRINE CHODOROWSKI-KIMMES**

---

L'Oréal  
1 Avenue Eugène Schueller  
BP 22 93601  
Aulnay sous Bois Cedex  
[SCHODOROWSKI@rd.loreal.com](mailto:SCHODOROWSKI@rd.loreal.com)

### **DR CHRISTOPHE COUDRET**

---

Laboratoire des IMRCP  
118 route de Narbonne,  
Bâtiment 2R1  
31062 Toulouse Cedex 09  
[coudret@chimie.ups-tlse.fr](mailto:coudret@chimie.ups-tlse.fr)

## **DR PHILIPPE DAUBAN**

---

Institut de Chimie des Substances Naturelles  
CNRS UPR2301  
Centre de Recherche de Gif  
Bâtiment 27,  
1, avenue de la Terrasse  
91198 Gif-sur-Yvette Cedex France  
[philippe.dauban@icsn.cnrs-gif.fr](mailto:philippe.dauban@icsn.cnrs-gif.fr)

## **DR EMMANUEL MAGNIER**

---

Université de Versailles St-Quentin  
Bâtiment Lavoisier , 45 avenue des Etats Unis  
78035 Versailles cedex  
[magnier@chimie.uvsq.fr](mailto:magnier@chimie.uvsq.fr)

## **DR ALAIN DE MESMAEKER**

---

Syngenta Crop Protection AG  
Schaffhauserstrasse  
CH-4332 Stein-Switzerland  
[Alain.de\\_mesmaeker@syngenta.com](mailto:Alain.de_mesmaeker@syngenta.com)

## ORAL COMMUNICATIONS

### A

---

**ALTMAYER-HENZIEN AMANDINE**

Laboratoire de Synthèse Organique & Méthodologie, ICMMO (UMR8182)  
Bât. 420, Université Paris–Sud 11, 91405 ORSAY Cedex, France  
[amandine.altmayer-henzien@u-psud.fr](mailto:amandine.altmayer-henzien@u-psud.fr)

**AOUN SAMEH**

Laboratoire CEISAM, UMR CNRS 6230, Université de Nantes,  
Faculté des Sciences et des Techniques,  
02 rue de la Houssinière – BP 92208 – 44322 NANTES Cedex 3  
[sameh.aoun@univ-nantes.fr](mailto:sameh.aoun@univ-nantes.fr)

**AUBE CHRISTOPHE**

CEISAM, UMR 6230  
2 rue de la Houssinière – 44322 NANTES  
[christophe.aube@univ-nantes.fr](mailto:christophe.aube@univ-nantes.fr)

### B

---

**BENSOUSSAN CHARLELIE**

ESPCI ParisTech, UMR 7084  
10 rue Vauquelin, 75231 Paris Cedex 05  
[DROUJTY@GMAIL.COM](mailto:DROUJTY@GMAIL.COM)

**BOLTE BENOIT**

DCSO, UMR 7652, CNRS/Ecole Polytechnique, 91128 Palaiseau, France  
[BOLTE@DCSO.POLYTECHNIQUE.FR](mailto:BOLTE@DCSO.POLYTECHNIQUE.FR)

**BORGHESE SOPHIE**

Laboratoire de Synthèse et Réactivité Organiques,  
Institut de Chimie, Université de Strasbourg, 4 rue Blaise Pascal, 67000 Strasbourg  
[SOPHIE.BORGHESE@ETU.UNISTRA.FR](mailto:SOPHIE.BORGHESE@ETU.UNISTRA.FR)

**BURA THOMAS**

*Laboratoire de Chimie Organique et Spectroscopies Avancées (LCOSA), UMR 7515  
au CNRS, Ecole de Chimie, Polymères, Matériaux de Strasbourg (ECPM),  
25 rue Becquerel, 67087 Strasbourg, Cedex 02, France  
[Thomas.bura@hotmail.fr](mailto:Thomas.bura@hotmail.fr)*

### C

---

**CAILLOT GILLES**

CNRS, LCC (Laboratoire de Chimie de Coordination)  
205 route de Narbonne, BP 44099, F-31077 Toulouse Cedex 4, France  
Université de Toulouse, UPS, INPT, F-31077 Toulouse Cedex 4, France  
[CAILLOT@LCC-TOULOUSE.FR](mailto:CAILLOT@LCC-TOULOUSE.FR)



**CATANA DAN-ANDREI**

Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique  
(UMR CNRS 5068)  
Université Paul Sabatier, 31062 Toulouse Cedex 9 (France)  
[CATANA@CHIMIE.UPS-TLSE.FR](mailto:CATANA@CHIMIE.UPS-TLSE.FR)

**CHAMAS ZEIN EL ABIDINE –**

Laboratoire SRSMC, UMR 7565, BP 70239,  
Bd des Aiguillettes, 54506 Vandoeuvre-Lès-Nancy-France  
Faculté des Sciences et Technologies, Université de Lorraine  
[Zein.El-Abidine-Chamas@srsmc.uhp-nancy.fr](mailto:Zein.El-Abidine-Chamas@srsmc.uhp-nancy.fr)

**CHARPENAY MELANIE**

Laboratoire d'Innovation Thérapeutique (UMR 7200)  
Équipe de synthèse de biomolécules, Faculté de Pharmacie, UMR UDS/CNRS 7200  
74 route du Rhin, 67401 Illkirch  
[MELANIE.CHARPENAY@ETU.UNISTRA.FR](mailto:MELANIE.CHARPENAY@ETU.UNISTRA.FR)

**CHEVAL NICOLAS**

Laboratoire de Synthèse et Réactivité Organiques,  
Institut de Chimie, Université de Strasbourg  
4 rue Blaise Pascal, 67000 Strasbourg  
[ncheval@unistra.fr](mailto:ncheval@unistra.fr)

**COMPAIN GUILLAUME**

Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), UMR CNRS 7285  
Université de Poitiers - 4, avenue Michel Brunet, F-86022 Poitiers Cedex, France  
Equipe « Glycochimie, Superacide et Chimie des systèmes »  
[GUILLAUME.COMPAIN@UNIV-POITIERS.FR](mailto:GUILLAUME.COMPAIN@UNIV-POITIERS.FR)

**CYKLINSKY MATHIEU**

UPMC-Univ Paris 06, Institut Parisien de Chimie Moléculaire (UMR CNRS 7201)  
Equipe Synthèses Sélectives et Organométalliques, Bâtiment F, 2<sup>ème</sup> étage C.183,  
4 place Jussieu, 75252 Paris cedex 5  
[mathieu.cyklinsky@upmc.fr](mailto:mathieu.cyklinsky@upmc.fr)

**D**

---

**DARDENNE JEREMY**

Centre de Recherche de Gif, Institut de Chimie des Substances Naturelles, 1 avenue  
de la terrasse 91198 Gif sur Yvette CEDEX  
[DARDEN@ICSN.CNRS-GIF.FR](mailto:DARDEN@ICSN.CNRS-GIF.FR)

**DECROOCQ CAMILLE**

Laboratoire de Synthèse Organique et Molécules Bioactives  
UMR 7509, UdS, CNRS, ECPM, 25 rue Becquerel, 67087 Strasbourg;  
[camille.decroocq@etu.unistra.fr](mailto:camille.decroocq@etu.unistra.fr)

**DEMORY EMILIEN**

Département de Chimie Moléculaire, UMR-5250, ICMG FR-2607, CNRS,  
Université Joseph Fourier, BP-53, 38041 Grenoble Cedex 9, France  
[emilien.demory@ujf-grenoble.fr](mailto:emilien.demory@ujf-grenoble.fr)

**DE SCHUTTER CORALIE**

Laboratoire de Chimie Moléculaire et Thio organique, ENSICAEN, UMR-CNRS 6507,  
6 Bd du Maréchal Juin, 14050 Caen, France  
[coralie.deschutter@ensicaen.fr](mailto:coralie.deschutter@ensicaen.fr)

**DESMARCHELIER ALARIC**

Institut Lavoisier de Versailles, Université de Versailles-Saint-Quentin-en-Yvelines  
45, avenue des Etats-Unis, 78035 Versailles Cedex, France  
[alaric.desmarchelier@chimie.uvsq.fr](mailto:alaric.desmarchelier@chimie.uvsq.fr)

**E**

---

**EL HELLANI AHMAD**

Université Paris-sud 11, ICMMO, UMR 8182, LCM  
Orsay, France  
[ahmad.el-hellani@u-psud.fr](mailto:ahmad.el-hellani@u-psud.fr)

**F**

---

**FRATH DENIS**

[Denis.fraith@etu.unistra.fr](mailto:Denis.fraith@etu.unistra.fr)

**G**

---

**GIBOULOT STEVEN**

IPCM, UPMC, UMR CNRS 7201  
4 Place Jusieu, case 183, 75252 Paris Cedex 05  
[STEVEN.GIBOULOT@UPMC.FR](mailto:STEVEN.GIBOULOT@UPMC.FR)

**GIROS AUDREY**

Laboratoire de Synthèse Organique et Méthodologie, ICMMO (UMR 8182)  
Bât. 420, Université Paris-Sud 11, 91405 Orsay Cedex, France  
[Audrey.Giros@u-psud.fr](mailto:Audrey.Giros@u-psud.fr)

**H**

---

**HEESCHER CAROLIN**

Johannes Gutenberg Universität Mainz, Duesbergweg 10-14, 55128 Mainz, Germany  
[HEESCHER@HOTMAIL.COM](mailto:HEESCHER@HOTMAIL.COM)

**HEMELAERE REMY**

UMR CNRS 6226, Sciences chimiques de Rennes, Université de Rennes 1.  
263 avenue du Général Leclerc, 35042 RENNES CEDEX, France  
[RHEMELAERE@GMAIL.COM](mailto:RHEMELAERE@GMAIL.COM)

**HONG XIANG**

LCM, ICMMO, UPS-11, 91405, Orsay  
[Xiang.hong@u-psud.fr](mailto:Xiang.hong@u-psud.fr)

**HUANG MIN**

Institut de Chimie des Substances Naturelles, Av de la Terrasse, 91190 Gif sur Yvette,  
France  
[min.huang@icsn.cnrs-gif.fr](mailto:min.huang@icsn.cnrs-gif.fr)

---

**I****IBRAHIM FARAH**

ICMMO - Université Paris - Sud 11, Equipe de catalyse moléculaire  
Bâtiment 420,  
91405 Orsay Cedex, France.  
[farah.ibrahim@u-psud.fr](mailto:farah.ibrahim@u-psud.fr)

---

**K****KERN NICOLAS**

Laboratoire de Synthèse et Réactivité Organiques, UMR 7177 associé au CNRS,  
Institut de Chimie, Université de Strasbourg  
4 rue Blaise Pascal, 67070 Strasbourg, France  
[nkern@unistra.fr](mailto:nkern@unistra.fr)

**KING MATHIAS**

Faculté de Pharmacie, 74 Route du Rhin, CS 60024  
67401 ILLKIRCH CEDEX  
[KING@BIOORGA.U-STRASBG.FR](mailto:KING@BIOORGA.U-STRASBG.FR)

**KONIEV OLEKSANDR**

Faculté de Pharmacie, 74 Route du Rhin, CS 60024  
67401 ILLKIRCH CEDEX  
[koniev@unistra.fr](mailto:koniev@unistra.fr)

**KOTERA NAOKO**

CEA Saclay DSV/IBiTec-S/SCBM/LMT  
91191 Gif-sur-Yvette  
[NAOKOTERA@GMAIL.COM](mailto:NAOKOTERA@GMAIL.COM)

**L****LENORMAND HUGO**

Institut Parisien de Chimie Moléculaire (UMR 7201),  
Equipe Chimie Organique de Synthèse  
Bat F, 2<sup>ème</sup> étage, Case 229  
4, place Jussieu- 75252 Paris cedex 05  
[hugolenormand@gmail.com](mailto:hugolenormand@gmail.com)

**LEPRONIER AYMERIC**

Chirosciences Team - Institut des Sciences Moléculaires de Marseille –  
UMR CNRS 7313 - Université Aix-Marseille  
Campus Scientifique de Saint Jérôme, 13397 Marseille Cedex 20  
[aymeric.lepronier@etu.univ-cezanne.fr](mailto:aymeric.lepronier@etu.univ-cezanne.fr)

**LIU WENJUN**

Laboratoire de chimie et biochimie des microorganismes,  
Institut de Chimie, Université de Strasbourg/CNRS UMR 717  
5 rue Blaise Pascal, 67070 Strasbourg, France.  
[liu@unistra.fr](mailto:liu@unistra.fr)

**M**

---

**MACÉ FRÉDÉRIC**

Département de Chimie Moléculaire (SERCO), UMR-5250,  
Université Joseph Fourier, 301 Rue de la Chimie,  
BP-53, 38041, Grenoble Cedex 9  
[frederic.mace@ujf-grenoble.fr](mailto:frederic.mace@ujf-grenoble.fr)

**MAOUGAL ESMA**

Laboratoire **CEISAM** (Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation),  
Groupe **SYMBIOSE** (Synthèse Multiétape et BIOSciencE),  
UMR CNRS 6230, 2 rue de la Houssinière-BP 92208-44322 Nantes Cedex 3  
[esma.maougal@etu.univ-nantes.fr](mailto:esma.maougal@etu.univ-nantes.fr)

**MASSIF CEDRIK**

Université de Rouen  
Equipe de Chimie Bio-Organique, COBRA-CNRS UMR 6014 & FR 3038  
Rue Lucien Tesniere, 76130 Mont Saint Aignan  
[cedrikmassif@gmail.com](mailto:cedrikmassif@gmail.com)

**MEDINA FLORIAN**

UCCS UMR CNRS 8181 - Université de Lille 1  
Equipe Catalyse, Chiralité et Chimie Fine  
ENSCL - C7 - BP 90108 - 59652 Villeneuve d'Ascq Cedex - France  
[florian.medina@ed.univ-lille1.fr](mailto:florian.medina@ed.univ-lille1.fr)

**MEDRAN NAVARRETE VINCENT**

CEA / I<sup>2</sup>BM / SHFJ  
Laboratoire de Radiochimie et de Radiopharmacie  
Bât 829, p. D102  
4 Place du Général Leclerc, 91406 Orsay  
[vincent.medran-navarrete@cea.fr](mailto:vincent.medran-navarrete@cea.fr)

**MELLAL DÉNIA**

UPMC – Institut Parisien de Chimie Moléculaire  
Equipe Glycochimie Organique Biologique et Supramoléculaire  
UMR CNRS 7201, 4 place Jussieu 75252 Paris Cedex 05  
[DENIA.MELLAL@UPMC.FR](mailto:DENIA.MELLAL@UPMC.FR)

**MICHAUX JÉRÔME**

S.E.R.C.O., Département de Chimie Moléculaire, UMR CNRS 5250  
Université Joseph Fourier-Grenoble, BP 53, 38041 GRENOBLE Cedex 9  
[jerome.michaux@ujf-grenoble.fr](mailto:jerome.michaux@ujf-grenoble.fr)

**MONTEL SONIA**

Institut Charles Gerhardt - AM2N – ENSCM - 8, Rue de l'Ecole Normale-F-34296  
Montpellier Cedex 5 – France  
[SONIA.MONTEL@ENSCM.FR](mailto:SONIA.MONTEL@ENSCM.FR)

**N**

---

**NAWAZ FAISAL**

Aix-Marseille Université, Équipe STéRéO  
Institut des Sciences Moléculaires de Marseille  
iSm2 CNRS UMR 7313 – Centre Saint Jérôme  
13397 Marseille Cedex 20 – France  
[faisal.nawaz@etu.univ-amu.fr](mailto:faisal.nawaz@etu.univ-amu.fr)

**NOEL AMANDINE**

Centre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS,  
1 Avenue de la Terrasse  
91190 Gif-sur-Yvette, France  
[amandine.noel@icsn.cnrs-gif.fr](mailto:amandine.noel@icsn.cnrs-gif.fr)

**P**

---

**PAGOAGA BERNANRD**

Université de Reims Champagne-Ardenne, UFR Sciences, B.P 1039  
F-51687 Reims Cedex 2  
[bernard.pagoaga@gmail.com](mailto:bernard.pagoaga@gmail.com)

**PESSET BENEDICTE**

"Transports Membranaires Bactériens", IREBS UMR 7242  
ESBS, Bvd Sébastien Brant, 67400 Illkirch-Graffenstaden  
[pesset@unistra.fr](mailto:pesset@unistra.fr)

**PIERRE CATHLEEN**

Université Claude Bernard Lyon 1 - UMR 5246 - Bâtiment CPE  
Domaine scientifique de la Doua  
43, Bd du 11 novembre 1918, Villeurbanne, France.  
[cathleen.pierre@gmail.com](mailto:cathleen.pierre@gmail.com)

**PRADHAN ANIRBAN**

Centre de Recherche Paul Pascal, CNRS & Université de Bordeaux,  
115 Avenue Schweitzer, 33600 Pessac (France)  
[pradhan@crpp-bordeaux.cnrs.fr](mailto:pradhan@crpp-bordeaux.cnrs.fr)

**PRIEM THOMAS**

IRCOF, Université de Rouen, rue Tesnières  
F-76131 Mont-Saint-Aignan cedex  
[thomas.priem@etu.univ-rouen.fr](mailto:thomas.priem@etu.univ-rouen.fr)

## Q

---

### **QU HUANHUAN**

Université Pierre et Marie Curie - Paris 6, Institut Parisien de Chimie Moléculaire (UMR 7201),  
Batiment F74, 2er étage, C. 181, 4 place Jussieu, 75005 Paris, France  
[aiby116@163.com](mailto:aiby116@163.com)

## R

---

### **RAFFIER LUDOVIC**

Université Lyon 1 – UMR CNRS 5246 – ICBMS – Laboratoire SURCOOF  
Bât. Raulin 3<sup>e</sup> étage – 43 Bd du 11 Novembre 1918  
69622 Villeurbanne CEDEX  
[ludovic.raffier64@gmail.com](mailto:ludovic.raffier64@gmail.com)

### **RAIMONDI WILFRIED**

UMR CNRS 7313 iSm2, Aix-Marseille Université Centre Saint Jérôme, service 531,  
13397 Marseille Cedex 20 (France)  
[raimondi.wilfried@gmail.com](mailto:raimondi.wilfried@gmail.com)

### **RAYA PACO**

Laboratoire de Synthèse et Réactivité Organiques – Université De Strasbourg  
4, rue Blaise Pascal – Institut Le Bel 67070 STRASBOURG Cedex  
[raya@unistra.fr](mailto:raya@unistra.fr)

### **RIFLADE BENOIT**

UPMC-Univ Paris 06, Institut Parisien de Chimie Moléculaire (UMR CNRS 7201)  
Bâtiment F, 2<sup>ème</sup> étage,  
4 place Jussieu, 75252 Paris cedex 5  
[benoit.riflade@upmc.fr](mailto:benoit.riflade@upmc.fr)

### **RIHN SANDRA**

Laboratoire de Chimie Moléculaire et Spectroscopies Avancées (LCOSA),  
Ecole Européenne de Chimie, Polymères et Matériaux,  
CNRS, (UMR 7515) 25 rue Becquerel, 67087 Strasbourg Cedex 02, France  
[sandra.rihn@etu.unistra.fr](mailto:sandra.rihn@etu.unistra.fr)

## S

---

### **SARKAR PARANTAP**

Centre de Recherche Paul Pascal, CNRS UPR8641 and Université de Bordeaux  
[sarkar@crpp-bordeaux.cnrs.fr](mailto:sarkar@crpp-bordeaux.cnrs.fr)

### **SBARGOUD KAMAL**

Institut Lavoisier, UMR CNRS 8180, Université de Versailles St Quentin en Y.  
45 avenue des Etats Unis, 78035 Versailles Cedex  
[kamasbar@chimie.uvsq.fr](mailto:kamasbar@chimie.uvsq.fr)

**SCHLEMMER CLAUDINE**

Johannes Gutenberg-Universität Mainz  
Duesbergweg 10-14, 55128 Mainz, Germany  
[SCHELMME@UNI-MAINZ.DE](mailto:SCHELMME@UNI-MAINZ.DE)

**SIGWALT DAVID**

Laboratoire de Chimie des Matériaux Moléculaires,  
Université de Strasbourg et CNRS (UMR 7509),  
Ecole Européenne de Chimie, Polymères et Matériaux (ECPM),  
25 rue Becquerel, 67087 Strasbourg Cedex 2, France.  
Laboratoire de Chimie Génétique, CAMB, Université de Strasbourg  
CNRS (UMR 7199), Faculté de Pharmacie, 74 route du Rhin,  
B.P. 60024, 67401 Illkirch, France.

**STOYE ALEXANDER**

Johannes Gutenberg-Universität Mainz  
Duesbergweg 10-14, 55128 Mainz, Germany  
[stoye@uni-mainz.de](mailto:stoye@uni-mainz.de)

**X**

---

**XU BIXUE**

UPMC- Paris 6, IPCM (UMR 7201)  
4 place Jussieu, 75005 Paris, France  
[bixue\\_xu@hotmail.com](mailto:bixue_xu@hotmail.com)

**Y**

---

**YANG JING**

ICMMO, LCM, UMR 8182, Université Paris Sud 11  
91405 Orsay Cedex, France  
[JING.YANG@U-PSUD.FR](mailto:JING.YANG@U-PSUD.FR)